{"product_id":"fundamentals-and-advances-in-immunotherapy-in-the-oncology-patient-2024","title":"Fundamentals and Advances in Immunotherapy in the Oncology Patient 2024","description":"\u003ch4 class=\"product_title entry-title\"\u003eFundamentals and Advances in Immunotherapy in the Oncology Patient 2024\u003c\/h4\u003e\u003cbr\u003eImmunotherapy in the Oncology Patient\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eInclude: 23 videos + 1 pdf, size: 5.44 GB\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Target Audience: physicians, and nurses who care for oncology patient\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSample video: \u003cspan style=\"color: #0000ff;\"\u003e\u003ca href=\"https:\/\/medicalamboss.com\/contact-us\/\" style=\"color: #0000ff;\"\u003econtact me\u003c\/a\u003e\u003c\/span\u003e for sample video\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location\u003c\/div\u003e\n\u003cbr\u003eWednesday, January 24, 2024, 8:00 AM – 5:20 PM, Online, New York , NY\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eSpecialties\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Allergy and Immunology, Bone Marrow Transplant, Breast Medical Oncology, Cellular Therapeutics, Critical Care, Dermatology, Endocrinology, Diabetes and Metabolism, Gastrointestinal Oncology, Genitourinary Oncology, Gynecologic Oncology, Head and Neck Oncology, Hepatology, Hospice and Palliative Medicine, Immunotherapy, Leukemia, Lymphoma, Medical Oncology, Neurology, Neuro-Oncology, Nurse Practitioner, Nursing, Oncology and Hematology, Pharmacology and Medication Management, Physician Assistant, Pulmonary Medicine, Radiation Oncology, Rheumatology, Solid Tumor Oncology\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003eOverview\u003c\/div\u003e\n\u003cbr\u003eImmunotherapy in the Oncology Patient\u003cbr\u003e\u003cbr\u003eImmunotherapeutics has changed the landscape of treatment modalities available to the cancer patient in both solid tumor and hematologic malignancies. Since the breakthrough of ipilimumab, there have been fast-paced and ongoing advancements in the field of immunotherapy, revolutionizing clinical management at a rapid pace.\u003cbr\u003e\u003cbr\u003eThis one-day virtual symposium will review fundamental concepts and recent advances in immunotherapy designed to meet the learning needs of advanced practice providers (APPs) and other allied health professionals. Clinical application in solid tumor and hematologic malignancies will be discussed as well as toxicity management, including immune-related adverse events resulting from immune checkpoint inhibition.\u003cbr\u003e\u003cbr\u003eExperts will discuss the fundamentals of immune checkpoint blockade and CAR T cell therapy, as well as advancements in TIL and BITE therapy, novel combination therapy, and algorithmic management of immune-related adverse events. Toxicity management will be communicated through case study applications and demonstration of common, rare, and severe immune-related adverse events.\u003cbr\u003e\u003cbr\u003eThe overall goal of this program is to improve cancer patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy through fundamental understanding and clinical application.\u003cbr\u003e\u003cbr\u003eAttendees of this symposium will receive access to an \u003cstrong\u003eonline syllabus\u003c\/strong\u003e, which includes select video recordings of the lectures.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eThe target audience for this course includes nurse practitioners, physician assistants, certified registered nurse anesthetists, physicians, and nurses who care for oncology patient.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eObjectives\u003c\/div\u003e\n\u003cdiv\u003eAt the conclusion of this symposium, learners will be able to:\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eDescribe the principles surrounding the immunity cycle\u003c\/li\u003e\n\u003cli\u003eExplain fundamental principles of immunotherapeutic agents including immune checkpoint inhibition, CAR T cell, TIL, and BITE therapies.\u003c\/li\u003e\n\u003cli\u003eDiscuss the symptoms of Cytokine release Syndrome, ICANS, prolonged cytopenias and clinical management\u003c\/li\u003e\n\u003cli\u003eRecognize and identify common, rare, and severe immune related adverse events attributed to immune checkpoint inhibition\u003c\/li\u003e\n\u003cli\u003eDiscuss clinical application of immune modulated agents in the oncology population\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAPPImmuno2024_Brochure.pdf\u003c\/li\u003e\n\u003cli\u003eArthralgias and Myalgias.mp4\u003c\/li\u003e\n\u003cli\u003eBenefit of Adjuvant Combination Therapy vs. Surveillance in High Risk Hepatocellular Carcinoma Patients.mp4\u003c\/li\u003e\n\u003cli\u003eClinical Landscape of Immunotherapy in Soft Tissue Sarcoma- Fundamentals and Advances in Immunotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eDermatologic irAEs.mp4\u003c\/li\u003e\n\u003cli\u003eFDA Approved CAR T Products in the Treatment and Management of Leukemia.mp4\u003c\/li\u003e\n\u003cli\u003eFundamentals of Chimeric Antigen Receptor (CAR) T Cell Immunotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eHepatotoxicty.mp4\u003c\/li\u003e\n\u003cli\u003eImmunotherapy and CAR T Cell Therapy in Hematologic Malignancies Lymphoma.mp4\u003c\/li\u003e\n\u003cli\u003eImmunotherapy Induced Diabletes Mellitus.mp4\u003c\/li\u003e\n\u003cli\u003eImplementation of Cellular Therapy in the Solid Tumor Population- The Use of TIL Therapy in Melanoma.mp4\u003c\/li\u003e\n\u003cli\u003eMechanism of Action of Checkpoint Blockade With a Focus on PD1, PDL1, and CTLA-4.mp4\u003c\/li\u003e\n\u003cli\u003eNeoadjuvant Combination Modalites in Resectable Non Small Cell Lung Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eNovel Checkpoint Inhibitors and Combination Therapy in the Clinical Setting.mp4\u003c\/li\u003e\n\u003cli\u003eNovel Immune Modulated Agents in the Treatment of Glioblastoma.mp4\u003c\/li\u003e\n\u003cli\u003eOverall Survival (OS) in Recurrent or Metastatic Cervical Cancer Using Combination Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eOverview of Adverse Events in the Cellular Therapy Patient- CRS, ICANS, and Prolonged Cytopenias.mp4\u003c\/li\u003e\n\u003cli\u003ePanel Discussion- Clinical Application of Immune Checkpoint Inhibitors in Solid Tumor Malignancy.mp4\u003c\/li\u003e\n\u003cli\u003ePanel Discussion- Clinical Application of Immune Therapy in Hematologic Malignancy.mp4\u003c\/li\u003e\n\u003cli\u003ePanel Discussion- Clinical Updates in Solid Tumor and Novel Immune Modulation.mp4\u003c\/li\u003e\n\u003cli\u003ePanel Discussion- Diagnosis and Clinical Management of Immune Related Adverse Events (irAE).mp4\u003c\/li\u003e\n\u003cli\u003ePanel Discussion- Fundamentals of T Cell Therapy.mp4\u003c\/li\u003e\n\u003cli\u003ePneumonitis.mp4\u003c\/li\u003e\n\u003cli\u003eT Cell Re-Directing Therapy in Multiple Myeloma.mp4\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954431823970,"sku":"MED-AMB03362","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Memorial-Sloan-Kettering-Cancer-Center-Fundamentals-and-Advances-in-Immunotherapy-in-the-Oncology-Patient-2024.jpg?v=1779376546","url":"https:\/\/meducourse.com\/products\/fundamentals-and-advances-in-immunotherapy-in-the-oncology-patient-2024","provider":"Meducourse","version":"1.0","type":"link"}